Browse by author
Lookup NU author(s): Rachel Telfer-Sutherland, Dr Annette Meeson, Dr Simon Lowes
This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).
© 2020, The Author(s).The solute carrier (SLC) superfamily encompasses a large variety of membrane-bound transporters required to transport a diverse array of substrates over biological membranes. Physiologically, they are essential for nutrient uptake, ion transport and waste removal. However, accumulating evidence suggest that up- and/or downregulation of SLCs may play a pivotal role in the pathogenesis of human malignancy. Endogenous substrates of SLCs include oestrogen and its conjugates, the handling of which may be of importance in hormone-dependent cancers. The SLCs play a significant role in the handling of therapeutic agents including anticancer drugs. Differential SLC expression in cancers may, therefore, impact on the efficacy of treatments. However, there is also a small body of evidence to suggest the dysregulated expression of some of these transporters may be linked to cancer metastasis. This review draws on the current knowledge of the roles of SLC transporters in human cancers in order to highlight the potential significance of these solute carriers in breast cancer pathogenesis and treatment. [Figure not available: see fulltext.]
Author(s): Sutherland R, Meeson A, Lowes S
Publication type: Review
Publication status: Published
Journal: Cancer and Metastasis Reviews
Year: 2020
Volume: 39
Pages: 919-932
Print publication date: 01/09/2020
Online publication date: 09/05/2020
Acceptance date: 02/04/2016
ISSN (print): 0167-7659
ISSN (electronic): 1573-7233
Publisher: Springer
URL: https://doi.org/10.1007/s10555-020-09879-6
DOI: 10.1007/s10555-020-09879-6
PubMed id: 32388639
